A practical reference on Cyclic heptapeptide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-09-20. Anything still debated is marked as such rather than presented as settled.
Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
Regulatory status varies by jurisdiction, where approved prescription products, compounded preparations and research-grade material are treated as distinct categories with different documentation requirements. Suppliers of research material commonly issue a certificate of analysis listing purity, identity and sometimes endotoxin content. Independent verification by a third-party laboratory is often recommended because self-reported figures are difficult to check. Literature discussions usually state the source, purity and storage conditions of the material used, since these details affect reproducibility. Analysts note that a reported purity figure does not by itself describe biological activity.
Lyophilised peptide is generally held below minus twenty degrees Celsius, protected from light and moisture, because hydrolysis and oxidation accumulate faster at ambient temperature. Once reconstituted, solutions are typically kept between two and eight degrees Celsius and used within a short window defined by the supplier. Repeated freeze-thaw cycles are avoided since they promote aggregation and loss of soluble material. Container material matters as well, because peptides adsorb to certain plastics and glass surfaces at low concentration. Stability figures supplied by a vendor apply only to the specific lot and buffer that were tested.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography combined with mass spectrometry. A gradient of water and acetonitrile containing trifluoroacetic acid is a common mobile phase, and ultraviolet detection near 214 nanometres responds to the peptide backbone. Mass spectrometry confirms the expected molecular mass and helps reveal truncation or oxidation products. Purity is reported as a peak-area percentage, a figure that depends on the wavelength and gradient used, so values from different laboratories are not always directly comparable. Peptide mapping and amino acid analysis provide additional confirmation when required.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Cyclic heptapeptide | Synthetic melanocortin analogue |
| Molecular formula | C50H68N14O10 | Corresponds to a mass near 1025 daltons |
| Appearance | White to off-white powder | Lyophilised solid before reconstitution |
| Solubility | Soluble in water and polar solvents | Poor solubility in nonpolar media |
| Common synonyms | Bremelanotide, PT-141 | Code name and international name used interchangeably |
Identity and purity are established with orthogonal methods rather than a single test. Reverse-phase high-performance liquid chromatography with ultraviolet detection gives a purity figure by area normalization, while mass spectrometry confirms the expected molecular ion. Amino acid analysis or peptide mapping can detect sequence errors that a mass value alone would miss, and residual counterion content is sometimes measured separately. Common impurities include truncated sequences, oxidized residues, and deamidated products; reporting them individually is more informative than a single composite purity number.
Lyophilized peptide arrives as a white to off-white cake or powder and is normally held at minus twenty degrees Celsius or colder for extended periods. Short-term bench work at ambient temperature is tolerable for minutes, not hours, because the solid is hygroscopic and picks up moisture that promotes hydrolysis. Vials should stay in a desiccator or a sealed bag with desiccant, protected from light, since aromatic residues in the sequence are susceptible to photo-oxidation. Inventory records that note arrival date and storage location reduce the chance of using degraded material.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
Evidence outside the studied population is sparse. Trials have concentrated on premenopausal women with a defined diagnosis, and data for postmenopausal women, men, and people taking interacting medications remain limited. Non-prescription use of the peptide for comparable goals is widespread but is not supported by published controlled data. Observed changes in blood pressure have drawn attention to cardiovascular monitoring during use. The literature generally frames the compound as a targeted receptor agonist rather than a general libido enhancer, and basic questions about mechanism and long-term safety are unresolved.
Bremelanotide functions as an agonist at several melanocortin receptor subtypes, with the strongest functional activity reported at the MC4 subtype. MC4 receptors sit in hypothalamic circuits that influence appetite, energy balance, and components of sexual behaviour. Rodents lacking functional MC4 receptors show altered mating behaviour, which supports a role for this pathway in desire. The precise sequence of events connecting receptor activation to reported human effects remains only partly characterised. Because the same receptor family governs pigmentation and inflammatory signalling, selectivity is a recurring theme in pharmacological discussion.
This was announced after the BBC had experimented with 8K during the London Olympics. On January 27, 2013, Asahi Shimbun reported that 4K Ultra HD satellite broadcasts would start in Japan with the 2014 FIFA World Cup. Japan's Ministry of Internal Affairs and Communications decided on this move to stimulate demand for 4K Ultra HD TVs. On February 21, 2013, Sony announced that the PlayStation 4 would support 4K resolution output for photos and videos but wouldn't render games at that resolution. On March 26, 2013, the Advanced Television Systems Committee (ATSC) announced a call for proposals for the ATSC 3.0 physical layer that specifies support for 3840 × 2160 resolution at 60 fps. On 11 April 2013, Bulb TV created by Canadian entrepreneur Evan Kosiner announced a 4K linear channel and VOD content to cable and satellite companies in North America. The channel planned to be licensed by the Canadian Radio-Television and Telecommunications Commission to provide educational content. On April 19, 2013, SES announced the first Ultra HD transmission using the High Efficiency Video Coding(HEVC) standard. The transmission had a resolution of 3840 × 2160 and a bit rate of 20 Mbit/s. On May 9, 2013, NHK and Mitsubishi Electric announced that they had jointly developed the first HEVC encoder for 8K Ultra HD TV, which is also called Super Hi-Vision (SHV). The HEVC encoder supports the Main 10 profile at Level 6.1 allowing it to encode 10 bpc video with a resolution of 7680 × 4320 at 60 fps.
== Applications == BSA is often used as a model for other serum albumin proteins, especially human serum albumin, to which it is 76% structurally homologous. BSA has numerous biochemical applications including ELISAs (Enzyme-Linked Immunosorbent Assay), immunoblots, and immunohistochemistry. Because BSA is a small, stable, moderately non-reactive protein, it is often used as a blocker in immunohistochemistry. During immunohistochemistry, which is the process that uses antibodies to identify antigens in cells, tissue sections are often incubated with BSA blockers to bind nonspecific binding sites. This binding of BSA to nonspecific binding sites increases the chance that the antibodies will bind only to the antigens of interest. The BSA blocker improves sensitivity by decreasing background noise as the sites are covered with the moderately non-reactive protein. During this process, minimization of nonspecific binding of antibodies is essential in order to acquire the highest signal to noise ratio. BSA is also used as a nutrient in cell and microbial culture. In restriction digests, BSA is used to stabilize some enzymes during the digestion of DNA and to prevent adhesion of the enzyme to reaction tubes, pipette tips, and other vessels. This protein does not affect other enzymes that do not need it for stabilization. BSA is also commonly used to determine the quantity of other proteins, by comparing an unknown quantity of protein to known amounts of BSA (see Bradford protein assay).
== Limitations of model == AIDA, like other model-based approaches, is not sufficiently accurate to be used for individual patient simulation or glycemic prediction. Therefore, as the program makes clear, it is not intended for insulin therapy planning and can only be used for teaching, self-learning, demonstration, or research purposes. While the AIDA software can simulate a wide variety of insulin dosage and diet (nutrition) adjustments, it should be stressed that the purpose of AIDA is to create a learning environment for communicating and training intuitive thinking when dealing with such adjustments. In this respect AIDA appears most of use for recreating clinical situations in diabetes care, rather than trying to predict best outcome.
=== EC 1.17.1 With NAD or NADP as acceptor === EC 1.17.1.1: CDP-4-dehydro-6-deoxyglucose reductase EC 1.17.1.2: now classified as EC 1.17.7.4, 4-hydroxy-3-methylbut-2-enyl diphosphate reductase EC 1.17.1.3: leucoanthocyanidin reductase EC 1.17.1.4: xanthine dehydrogenase EC 1.17.1.5: nicotinate dehydrogenase EC 1.17.1.6: Now EC 1.17.99.5, bile-acid 7α-dehydroxylase. It is now known that FAD is the acceptor and not NAD+ as was thought previously EC 1.17.1.7: Now EC 1.2.1.91, 3-oxo-5,6-dehydrosuberyl-CoA semialdehyde dehydrogenase EC 1.17.1.8: 4-hydroxy-tetrahydrodipicolinate reductase EC 1.17.1.9: formate dehydrogenase EC 1.17.1.10: formate dehydrogenase (NADP+) EC 1.17.1.11: formate dehydrogenase (NAD+, ferredoxin)
== Structure == Serous membranes have two layers. The parietal layers of the membranes line the walls of the body cavity (pariet- refers to a cavity wall). The visceral layer of the membrane covers the organs (the viscera). Between the parietal and visceral layers is a very thin, fluid-filled serous space, or cavity.
Sources: en.wikipedia.org
== History == Founded in 1993 by Jack Owoc, Bang's parent company manufactured and distributed sports supplements and performance beverages under the brand name VPX. Other products distributed by Vital included Redline, Noo Fuzion, and Meltdown. In 2012, Vital created Bang, marketed as a low sugar carbonated energy drink and with the mission to make high-quality nutritional supplements backed by scientific research. In 2017, it was announced that Bang would offer a caffeine-free variant of the beverage, using beta-alanine in place of caffeine. In 2019, the company opened a manufacturing and distribution facility in Phoenix, Arizona, which operates alongside their facility in Pembroke Pines, Florida. In April 2020, PepsiCo entered into an exclusive distribution agreement with VPX to distribute Bang in the United States. On November 17, 2020, it gave PepsiCo a notice of termination; an emergency arbitrator ruled in December 2020 that Pepsi remained the exclusive distributor of Bang drinks until 2023. VPX resolved their disputes with PepsiCo and transitioned away from their distribution in June 2022. In August 2022, it was reported that Keurig Dr Pepper was in talks to purchase VPX; these talks fell apart shortly after the reports surfaced. On October 10, 2022, Bang's parent company filed for Chapter 11 bankruptcy protection. Three months after Owoc was removed and John DiDonato was named interim CEO of VPX, Monster Beverage reached an agreement for its purchase on June 28, 2023, this was completed one month later.
The decision to release the declaration was taken by the British War Cabinet on 31 October 1917. This followed discussion at four War Cabinet meetings (including the 31 October meeting) over the space of the previous two months. In order to aid the discussions, the War Cabinet Secretariat, led by Maurice Hankey, the Cabinet Secretary and supported by his Assistant Secretaries – primarily Sykes and his fellow Conservative MP and pro-Zionist Leo Amery – solicited outside perspectives to put before the Cabinet. These included the views of government ministers, war allies – notably from President Woodrow Wilson – and in October, formal submissions from six Zionist leaders and four non-Zionist Jews. British officials asked President Wilson for his consent on the matter on two occasions – first on 3 September, when he replied the time was not ripe, and later on 6 October, when he agreed with the release of the declaration.
Sulfur–sulfur bonds are a structural component used to stiffen rubber, similar to the disulfide bridges that rigidify proteins (see biological below). In the most common type of industrial "curing" or hardening and strengthening of natural rubber, elemental sulfur is heated with the rubber to the point that chemical reactions form disulfide bridges between isoprene units of the polymer. This process, patented in 1843, made rubber a major industrial product, especially in automobile tires. Because of the heat and sulfur, the process was named vulcanization, after the Roman god of the forge and volcanism.
A ribosome () is a ribonucleoprotein particle found in all cells that synthesizes proteins by translating genetic information encoded in messenger RNA (mRNA). During translation, the ribosome decodes successive codons in an mRNA molecule and, with the aid of transfer RNA (tRNA), links amino acids into a polypeptide chain. Each ribosome comprises a small and a large subunit, each composed of one or more ribosomal RNA (rRNA) molecules and many ribosomal proteins. Ribosomes differ in size, composition and organization among bacteria, archaea and eukaryotes, but they share a core structure that reflects a common evolutionary origin. Distinct ribosomes are also found in eukaryotic mitochondria and, in plants and algae, chloroplasts. Ribosomes are assembled through ribosome biogenesis, which involves rRNA synthesis and processing together with the assembly of ribosomal proteins into functional subunits. First observed by George Emil Palade in 1955, ribosomes have been the subject of extensive structural and functional research. Their discovery was recognized by the Nobel Prize in Physiology or Medicine in 1974, while determination of their atomic structure and mechanism through X-ray crystallography and cryo-electron microscopy was recognized by the Nobel Prize in Chemistry in 2009.
Tang Chinese soldiers and pirates enslaved Koreans, Turks, Persians, Indonesians, and people from Inner Mongolia, central Asia, and northern India. The greatest source of slaves came from southern tribes, including Thais and aboriginals from the southern provinces of Fujian, Guangdong, Guangxi, and Guizhou. Malays, Khmers, Indians, and "black skinned" peoples (who were either Austronesian Negritos of Southeast Asia and the Pacific Islands, or Africans, or both) were also purchased as slaves in the Tang dynasty. In the 17th century Qing dynasty, there was a hereditarily servile people called Booi Aha (Manchu: booi niyalma; Chinese transliteration: 包衣阿哈), which is a Manchu word literally translated as "household person" and sometimes rendered as "nucai." The Manchu was establishing close personal and paternalist relationship between masters and their slaves, as Nurhachi said, "The Master should love the slaves and eat the same food as him". However, booi aha "did not correspond exactly to the Chinese category of "bond-servant slave" (Chinese:奴僕); instead, it was a relationship of personal dependency on a master which in theory guaranteed close personal relationships and equal treatment, even though many western scholars would directly translate "booi" as "bond-servant" (some of the "booi" even had their own servant). Chinese Muslim (Tungans) Sufis who were charged with practicing xiejiao (heterodox religion), were punished by exile to Xinjiang and being sold as a slave to other Muslims, such as the Sufi begs.
Sources: en.wikipedia.org
PT-141 is a laboratory code for bremelanotide, a synthetic peptide that activates melanocortin receptors. It has been developed both as an injectable pharmaceutical product and as a research chemical. The two contexts differ sharply in how identity, purity, and dosing are controlled.
It is neither a steroid nor a naturally occurring human hormone. Bremelanotide is a manufactured peptide that mimics part of the melanocortin signalling system by binding receptor proteins. Its effects come from receptor activation, not from replacing a circulating hormone.
The internal lactam bridge locks the peptide into a defined shape, which raises receptor affinity and slows enzymatic breakdown. Linear versions of the same sequence are less stable and bind more weakly. Ring geometry is therefore central to how the molecule behaves in the body.
Purity is normally expressed as a percentage of total peak area from a chromatographic run. The value depends on the column, gradient and detection wavelength chosen. Results generated under different conditions are therefore not always interchangeable.